Market Data
Market Cap₹439.44 Cr.
52W High₹454
Current Price₹324
52W Low₹210.1
Down from 52W High28.6 %
Face Value₹10
Performance
ROCE4.82 %
ROE3.93 %
EPS (TTM)₹1.36
EPS Prev Qtr₹3.28
EPS Last Year₹1.56
EBITDA Qtr₹2.54 Cr.
Book Value₹204
Financial Health
Debt/Equity0.17
Debt/Profit4.76
Total Assets₹371.99 Cr.
Dividend Yield0.31 %
Promoter Holding40.46 %
Earning Power3.25 %
Valuation
Stock P/E43.72
Industry P/E33.3
Price to Book1.59
Price to Sales2.17
Graham Number₹184.32
Key Metrics
__derived
1
Face Value
₹10
About Medicamen Biotech Ltd
Healthcare · Pharmaceuticals
Medicamen Biotech Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹439.44 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 11.3% YoY, Profit grew 15.6% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 43.04 | 47.17 | 46.91 | 60.65 | 47.9 |
| ↳ QoQ Growth | - | +9.6% | -0.6% | +29.3% | -21.0% |
| Expenses | 40.23 | 43.87 | 44.36 | 56.94 | 45.36 |
| Operating Profit | 2.81 | 3.3 | 2.55 | 3.71 | 2.54 |
| OPM % | 6.53% | 7% | 5.44% | 6.12% | 5.3% |
| Other Income | 0.47 | 0.37 | 0.53 | 1.74 | 0.86 |
| Interest | 1.15 | 0.99 | 0.97 | 0.38 | 0.83 |
| Depreciation | 1.8 | 1.86 | 1.83 | 1.73 | 1.79 |
| EBITDA | 4.61 | 5.16 | 4.38 | 5.44 | 4.33 |
| EBITDA Margin % | 10.71% | 10.94% | 9.34% | 8.97% | 9.04% |
| Profit Before Tax | 2.13 | 2.68 | 2.11 | 5.06 | 2.57 |
| Tax % | 24.88% | 21.27% | 22.75% | 12.06% | 28.4% |
| Net Profit | 1.6 | 2.11 | 1.63 | 4.45 | 1.85 |
| ↳ QoQ Growth | - | +31.9% | -22.7% | +173.0% | -58.4% |
| EPS | 1.18 | 1.56 | 1.21 | 3.28 | 1.36 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 197.77 | 202.63 |
| Expenses | 185.4 | 190.53 |
| Operating Profit | 12.37 | 12.1 |
| OPM % | 6.25% | 5.97% |
| Other Income | 3.11 | 3.5 |
| Interest | 3.49 | 3.17 |
| Depreciation | 7.22 | 7.21 |
| Profit Before Tax | 11.98 | 12.42 |
| Tax % | 18.28% | 19.24% |
| Net Profit | 9.79 | 10.04 |
| EPS | 7.23 | 7.41 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
9.81%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
4.71%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 12.7146 | 13.56 |
| Reserves | 200.3384 | 261.99 |
| Borrowings | 33.25 | 47.78 |
| Other Liabilities | 50.85 | 48.66 |
| Total Liabilities | 297.1505 | 371.99 |
| Fixed Assets | 87.1044 | 84.09 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 210.05 | 287.9 |
| Total Assets | 297.1505 | 371.99 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -8.1588 |
| Cash from Investing Activity | -1.3968 |
| Cash from Financing Activity | -1.4706 |
| Net Cash Flow | -11.0262 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 598.35 |
| ROCE % | 3.82% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 40.46% | 40.46% | 40.46% | 40.46% |
| FIIs % | 0.06% | 0.02% | 0.1% | 0.07% |
| DIIs % | 0.59% | 0.44% | 0% | 0.4% |
| Public % | 33.35% | 32.17% | 32.09% | 32.1% |
| No. of Shareholders | 11,177 | 10,967 | 10,806 | 11,047 |
Major Shareholders (>1%)
- Shivalik Rasayan LimitedPromoter and Promoter Group40.46%
- Pharmadanica A/sPublic Shareholding9.88%
- Veralogix Holdings(pty) LtdPublic Shareholding4.42%
- Ginnerup Capital ApsPublic Shareholding2.62%
As of 2026-06-30View all shareholders →